TLDR:
- Waypoint Bio, a biotechnology company based in NYC, raised $14.5M in Seed funding led by Hummingbird Ventures.
- The company plans to use the funds to enhance its CAR T-cell therapies for solid tumors and develop Treg therapies for autoimmune diseases.
In a recent development, Waypoint Bio, a NYC-based biotechnology company, announced that it has successfully raised $14.5M in Seed funding. The funding round was led by Hummingbird Ventures, with participation from other investors such as Recode Ventures and pre-seed lead Fifty Years. The company, co-founded by CEO Xinchen Wang and CSO David Phizicky, is focused on providing novel cell therapies for solid tumors.
Waypoint Bio plans to utilize the raised funds to further enhance its CAR T-cell therapies, with a specific focus on improving efficacy against the tumor microenvironment. Additionally, the company aims to develop Treg therapies for autoimmune diseases using its proprietary spatial pooled screening technology and lab-in-the-loop approach. This strategic focus on both cancer and autoimmune diseases highlights the versatility and potential impact of Waypoint Bio’s technology.
The company’s team, which includes 11 researchers, scientists, and engineers, is supported by a diverse and expert Scientific Advisory Board, consisting of prominent figures such as Melina Claussnitzer from the Broad Institute of Harvard & MIT, Robbie Majzner from the Dana-Farber Cancer Institute, and Yvonne Chen from UCLA, among others. This strong foundation of scientific expertise positions Waypoint Bio for continued innovation and success in the field of biotechnology.
Overall, the successful Seed funding round and strategic focus on novel cell therapies for solid tumors and autoimmune diseases demonstrate Waypoint Bio’s commitment to driving advancements in the biotechnology industry. With a strong team and innovative technology at its core, the company is poised to make significant contributions to the field in the coming years.
